title: The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
abstract: BACKGROUND
  The role of cytoreductive nephrectomy in metastatic clear cell renal cell carcinoma (ccRCC) is controversial.
  
  
  OBJECTIVE
  To determine the outcome of patients with metastatic ccRCC who receive sunitinib prior to planned nephrectomy.
  
  
  METHODS
  The study combined the data from two prospective phase 2 studies that assessed upfront sunitinib (12-16 wk) prior to nephrectomy in previously untreated patients with metastatic renal cell carcinoma (RCC). Sunitinib was discontinued during the perioperative period (median: 29 d).
  
  
  METHODS
  Sunitinib 50mg in six weekly cycles (4 wk on, 2 wk off).
  
  
  METHODS
  Progression-free (PFS) and overall survival (OS) using the Kaplan-Meier method.
  
  
  CONCLUSIONS
  Twenty-one patients (32%) had Memorial Sloan-Kettering Cancer Centre (MSKCC) poor-risk disease; 45 (68%) had intermediate-risk disease. Nephrectomy was not performed in 19 (29%), most commonly due to disease progression (n = 12). The PFS for the cohort was 6.3 mo (95% confidence interval [CI], 5.1-8.5). Seventeen (36%) patients progressed during the treatment break, 13 (76%) of whom stabilised upon reinitiating of sunitinib. The OS for the cohort was 15.2 mo (95% CI, 10.3-NA). The OS for the intermediate MSKCC risk group was significantly longer than that for the poor-risk group (26.0 mo [95% CI, 13.6-NA] and 9.0 mo [95% CI, 5.8-20.5], respectively; p < 0.01). In multivariate analysis, progression of disease prior to planned nephrectomy (hazard ratio [HR]: 5.34; 95% CI, 3.17-13.27), high Fuhrman grade (HR 3.27; 95% CI, 1.38-7.72), and MSKCC poor risk at diagnosis (HR 4.75; 95% CI, 2.05-11.02) were associated with short survival (p < 0.01). However, in the absence of randomised studies it is not possible to determine if this approach is beneficial.
  
  
  CONCLUSIONS
  Upfront sunitinib prior to planned nephrectomy in intermediate-risk disease is associated with a median survival of >2 yr despite frequent progression during treatment break. Progression in metastatic sites prior to planned surgery and MSKCC poor-risk disease was associated with a poor outcome.
authors: Bart Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital London, UK.
authors: Thomas
authors: T
authors: Powles
authors: Christian
authors: C
authors: Blank
authors: Simon
authors: S
authors: Chowdhury
authors: Simon
authors: S
authors: Horenblas
authors: John
authors: J
authors: Peters
authors: Jonathan
authors: J
authors: Shamash
authors: Naveed
authors: N
authors: Sarwar
authors: Ekaterini
authors: E
authors: Boleti
authors: Anju
authors: A
authors: Sahdev
authors: Tim
authors: T
authors: O'Brien
authors: Dan
authors: D
authors: Berney
authors: Luis
authors: L
authors: Beltran
authors: Paul
authors: P
authors: Nathan
authors: John
authors: J
authors: Haanen
authors: Axel
authors: A
authors: Bex